Report Content
Chapter 1 Methodology & Scope
1.1 Market segmentation
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculations
1.3.2 Key trends for market estimates
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising in cancer prevalence
3.2.1.2 Growing demand for minimally invasive diagnostic procedures
3.2.1.3 Recent technological advancements in carcinoembryonic antigen diagnostics
3.2.1.4 Increasing per capita healthcare expenditure
3.2.2 Industry pitfalls & challenges
3.2.2.1 Inability to detect early-stage cancer
3.2.2.2 Lack of awareness regarding the application of carcinoembryonic antigen tests
3.3 Growth potential analysis
3.4 Regulatory landscape
3.4.1 U.S.
3.4.2 Europe
3.5 Global incidence of top cancers, by region, 2023
3.5.1 North America cancer incidence
3.5.2 Europe cancer incidence
3.5.3 Asia Pacific cancer incidence
3.5.4 Latin America cancer incidence
3.5.5 Middle East & Africa cancer incidence
3.6 Clinical studies landscape
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.1.1 F. Hoffmann-La Roche Ltd.
4.1.2 Quest Diagnostics Incorporated
4.1.3 Thermo Fisher Scientific Inc.
4.2 Competitive analysis of major market players
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Gastrointestinal cancer
5.2.1 Colorectal cancer
5.2.2 Pancreatic cancer
5.2.3 Liver cancer
5.2.4 Stomach cancer
5.2.5 Esophageal cancer
5.2.6 Gall bladder cancer
5.2.7 Anal cancer
5.3 Breast cancer
5.4 Lung cancer
5.5 Ovarian cancer
5.6 Prostate cancer
5.7 Thyroid cancer
Chapter 6 Market Estimates and Forecast, By Gender, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Male
6.3 Female
Chapter 7 Market Estimates and Forecast, By End-user, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Diagnostic laboratories
7.4 Oncology clinics
7.5 Research centers and academic institutes
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Poland
8.3.7 Russia
8.3.8 Sweden
8.3.9 Switzerland
8.3.10 Netherlands
8.3.11 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 New Zealand
8.4.7 Malaysia
8.4.8 Singapore
8.4.9 Indonesia
8.4.10 Philippines
8.4.11 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Columbia
8.5.5 Peru
8.5.6 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Abcam Limited
9.2 AdvaCare Pharma
9.3 Aviva Systems Biology Corporation
9.4 Boster Biological Technology
9.5 Creative Diagnostics
9.6 Diazyme Laboratories Inc.
9.7 F. Hoffmann-La Roche Ltd.
9.8 Medix Biochemica
9.9 Omega Diagnostics Ltd.
9.10 RayBiotech, Inc.
9.11 Thermo Fisher Scientific Inc.
9.12 Quest Diagnostics Incorporated
